Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

The Reverse Proteomics for Identification of Tumor Antigens

  • Lee, Sang-Yull (Department of Biochemistry, School of Medicine, Pusan National University) ;
  • Jeoung, Doo-Il (School of Biological Sciences, College of Natural Sciences, Kangwon National University)
  • Published : 2007.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The identification of tumor antigens is essential for the development of anticancer therapeutic vaccines and clinical diagnosis of cancer. SEREX (serological analysis of recombinant cDNA expression libraries) has been used to identify such tumor antigens by screening sera of patients with cDNA expression libraries. SEREX-defined antigens provide markers for the diagnosis of cancers. Potential diagnostic values of these SEREX-defined antigens have been evaluated. SEREX is also a powerful method for the development of anticancer therapeutics. The development of anticancer vaccines requires that tumor antigens can elicit antigen-specific antibodies or T lymphocytes. More than 2,000 antigens have been discovered by SEFEX. Peptides derived from some of these antigens have been evaluated in clinical trials. This review provides information on the application of SEREX for identification of tumor-associated antigens (TAA) for the development of cancer diagnostics and anticancer therapeutics.

Keywords

References

  1. Adrain, C., B. M. Murphy, and S. J. Martin. 2005. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J. Biol. Chem. 280: 4663-4673 https://doi.org/10.1074/jbc.M410915200
  2. Baurain, J. F., D. Colau, N. van Baren, C. Landry, V. Martelange, M. Vikkula, T. Boon, and P. G. Coulie. 2000. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J. Immunol. 164: 6057-6066 https://doi.org/10.4049/jimmunol.164.11.6057
  3. Benlalam, H., B. Linard, Y. Guilloux, A. Moreau-Aubry, L. Derre, E. Diez, B. Dreno, F. Jotereau, and N. Labarriere. 2003. Identification of five new HLA-B3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J. Immunol. 171: 6283-6289 https://doi.org/10.4049/jimmunol.171.11.6283
  4. Bjorkman, P. J. 1997. MHC restriction in three dimensions: A view of T cell receptor/ligand interactions. Cell 89: 167- 170 https://doi.org/10.1016/S0092-8674(00)80195-6
  5. Boel, P., C. Wildmann, M. L. Sensi, R. Brasseur, J. C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2: 167-175 https://doi.org/10.1016/S1074-7613(95)80053-0
  6. Boon, T., O. G. Coulie, and B. Van den Eynde. 1997. Tumor antigens recognized by T cells. Immunol. Today 18: 267
  7. Brandle, D., F. Brasseur, P. Weynants, T. Boon, and B. van den Eynde. 1996. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183: 2501-2508 https://doi.org/10.1084/jem.183.6.2501
  8. Butterfield, L. H., A. Koh, W. Meng, C. M. Vollmer, A. Ribas, V. Dissette, E. Lee , J. A. Glaspy, W. H. McBride, and J. S. Economou. 1999. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 59: 3134-3142
  9. Calhoun, R. F., B. Naziruddin, F. Enriquez-Rincon, B. F. Duffy, J. M. Ritter, S. Sundarsen, G. A. Patterson, J. D. Cooper, and T. Mohanakumar. 2000. Evidence for cytotoxic T lymphocyte response against human lung cancer: Reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I. Surgery 128: 76-85 https://doi.org/10.1067/msy.2000.106639
  10. Chen, Y. T., M. J. Scanlan, U. Sahin, O. Tureci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94L: 1914-1918
  11. Cho, B., H. Lee, S. Jeong, Y. J. Bang, H. J. Lee, K. S. Hwang, H. Y. Kim, Y. S. Lee, G. H. Kang, and D. I. Jeoung. 2003. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem. Biophys. Res. Commun. 307: 52-63 https://doi.org/10.1016/S0006-291X(03)01121-5
  12. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719 https://doi.org/10.1126/science.7513441
  13. Fay, J. W., A. K. Palucka, S. Paczesny, M. Dhodapkar, D. A. Johnston, S. Burkeholder, et al. 2006. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol. Immunother. 55: 1209-1218 https://doi.org/10.1007/s00262-005-0106-6
  14. Fernandez Madrid, F., R. L. Karvonen, M. J. Kraut, B. Czelusniak, and J. W. Ager. 1996. Autoimmunity to collagen in human lung cancer. Cancer Res. 56: 121-126
  15. Figueiredo, D. L., R. C. Mamede, R. Proto-Siqueira, L. Neder, W. A. Silva, and M. A. Zago. 2006. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 28: 614-619 https://doi.org/10.1002/hed.20380
  16. Gambacorti-Passerini, C., F. Grignani, F. Arienti, P. P. Pandolfi, P. G. Pelicci, and G. Parmiani. 1993. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 81: 1369-1375
  17. Gong, J., N. Nikrui, D. Chen, S. Koido, Z. Wu, and Y. Tanaka. 2000. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165: 1705-1711 https://doi.org/10.4049/jimmunol.165.3.1705
  18. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49: 281-355 https://doi.org/10.1016/S0065-2776(08)60778-6
  19. Grohmann, U., R. Bianchi, E. Ayroldi, M. L. Belladonna, D. Surace, and M. C. Fioretti. 1997. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol. 158: 3593-3602
  20. Groeper, C., F. Gambazzi, P. Zajac, L. Bubendorf, M. Adamina, R. Rosenthal, H. R. Zerkowski, M. Heberer, and G. C. Spagnoli. 2007. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int. J. Cancer 120: 337-343 https://doi.org/10.1002/ijc.22309
  21. Gueguen, M., J. J. Patard, B. Gaugler, F. Brasseur, J. C. Renauld, P. J. Van Cangh, T. Boon, and B. J. van den Eynde. 1998. An antigen recognized by autologous CTLs on a human bladder carcinoma. J. Immunol. 160: 6188-6194
  22. Heckel, D., N. Comtesse, N. Brass, N. Blin, K. D. Zang, and E. Meese. 1997. Novel immunogenic antigen homologous to hyaluronidase in meningioma. Hum. Mol. Genet. 6: 33-39 https://doi.org/10.1093/hmg/6.1.33
  23. Hunt, D. F., R. A. Henderson, J. Shabanowitz, K. Sakaguchi, H. Michel, N. Sevilir, A. L. Cox, E. Appella, and V. H. Engelhard. 1992. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255: 1261-1263 https://doi.org/10.1126/science.1546328
  24. Ichiki, Y., M. Takenoyama, M. Mizukami, T. So, M. Sugaya, M. Yasuda, T. So, T. Hanagiri, K. Sugio, and K. Yasumoto. 2004. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J. Immunol. 172: 4844-4850 https://doi.org/10.4049/jimmunol.172.8.4844
  25. Iwata, T., T. Fujita, N. Hirao, Y. Matsuzaki, T. Okada, H. Mochimaru, N. Susumu, E. Matsumoto, K. Sugano, N. Yamashita, S. Nozawa, and Y. Kawakami. 2005. Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer. Clin. Cancer Res. 119: 3949-3957
  26. Jager, D., E. Stockert, A. O. Gure, M. J. Scanlan, J. Karbach, E. Jager, A. Knuth, L. J. Old, and Y. T. Chen. 2001. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 61: 2055-2061
  27. Jager, E., J. Karbach, S. Gnjatic, A. Neumann, A. Bender, D. Valmori, M. Ayyoub, E. Ritter, G. Ritter, D. Jager, D. Panicali, E. Hoffman, L. Pan, H. Oettgen, L. J. Old, and A. Knuth. 2006. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1- specific immune responses in cancer patients. Proc. Natl. Acad. Sci. USA 103: 14453-14458
  28. Jager, E., Y. T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, L. J. Old, and A. Knuth. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187: 265-270 https://doi.org/10.1084/jem.187.2.265
  29. Khong, H. T., J. C. Yang, S. L. Topalian, R. M. Sherry, S. A. Mavroukakis, D. E. White, and S. A. Rosenberg. 2004. Immunization of HLA-A0201 and/or HLA-DPbeta104 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 27: 472-477 https://doi.org/10.1097/00002371-200411000-00007
  30. Koido, S., E. Hara, S. Homma, A. Torii, Y. Toyama, H. Kawahara, M. Watanabe, K. Yanaga, K. Fujise, H. Tajiri, J. Gong, and G. Toda. 2005. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11: 7891- 7900 https://doi.org/10.1158/1078-0432.CCR-05-1330
  31. Kono, K., Y. Rongcun, J. Charo, F. Ichihara, E. Celis, A. Sette, E. Appella, T. Sekikawa, Y. Matsumoto, and R. Kiessling. 1998. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int. J. Cancer 78: 202-208 https://doi.org/10.1002/(SICI)1097-0215(19981005)78:2<202::AID-IJC14>3.0.CO;2-C
  32. Lepage, S. and R. Lapointe. 2006. Melanosomal targeting sequences from gp100 are essential for MHC class IIrestricted endogenous epitope presentation and mobilization to endosomal compartments. Cancer Res. 66: 2423-2432 https://doi.org/10.1158/0008-5472.CAN-05-2516
  33. Line, A., Z. Slucka, A. Stengrevics, K. Silina, G. Li, and R. C. Rees. 2002. Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol. Immunother. 51: 574-582 https://doi.org/10.1007/s00262-002-0322-2
  34. Liu, G., H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu. 2004. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 64: 4980-4986 https://doi.org/10.1158/0008-5472.CAN-03-3504
  35. Lonchay, C., P. van der Bruggen, T. Connerotte, T. Hanagiri, P. Coulie, and D. Colau. 2004. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. USA 101: 14631-14638
  36. Maczek, C., T. G. Berger, B. Schuler-Thurner, E. S. Schultz, A. Hamann, P. R. Dunbar, V. Cerundolo, A. Steinkasserer, and G. Schuler. 2005. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase-, and influenza matrix peptide-specific CTL in HLA-A0201 melanoma patients. Int. J. Cancer 115: 450-455 https://doi.org/10.1002/ijc.20901
  37. Marchand, M., N. Van Baren, P. Weynants, V. Brichard, B. Dreno, M. H. Tessier, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80: 219-230 https://doi.org/10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S
  38. Mischo, A., A. Wadle, K. Watzig, D. Jager, E. Stockert, D. Santiago, et al. 2003. Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immun. 3: 5
  39. Muul, L. M., P. J. Spiess, E. P. Director, and S. A. Rosenberg. 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138: 989-995
  40. Ohkouchi, S., N. Kawamoto, M. Koga, F. Sakanashi, S. Shichijo, Y. Saijo, T. Nukiwa, K. Itoh, and A. Yamada. 2003. Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: A peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients. Eur. J. Immunol. 33: 2964-2973 https://doi.org/10.1002/eji.200324149
  41. Ottaviani, S., Y. Zhang, T. Boon, and P. van der Bruggen. 2005. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunol. Immunother. 54: 1214-1220 https://doi.org/10.1007/s00262-005-0705-2
  42. Posner, J. B. 1997. Paraneoplastic syndromes: A brief review. Ann. NY Acad. Sci. 835: 83-90 https://doi.org/10.1111/j.1749-6632.1997.tb48620.x
  43. Prins, R. M., S. K. Odesa, and L. M. Liau. 2003. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 63: 8487- 8491
  44. Reich, N. C., M. Oren, and A. J. Levine. 1983. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol. 3: 2143-2150 https://doi.org/10.1128/MCB.3.12.2143
  45. Rivoltini, L., P. Squarcina, D. J. Loftus, C. Castelli, P. Tarsini, A. Mazzocchi, et al. 1999. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: Implication for more effective immunotherapy. Cancer Res. 59: 301-306
  46. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, et al. 1995. Induction of tumorreactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154: 2257-2265
  47. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. 1988. N. Engl. J Med. 319: 1676-1680 https://doi.org/10.1056/NEJM198812223192527
  48. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, et al. 1999. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163: 1690-1695
  49. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, M. R. Parkhurst, Y. Kawakami, C. A. Seipp, J. H. Einhorn, and D. E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327 https://doi.org/10.1038/nm0398-321
  50. Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M. Pfreundschuh. 1995. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92: 11810-11813
  51. Sakakura, C., K. Hasegawa, K. Miyagawa, S. Nakashima, T. Yoshikawa, S. Kin, Y. Nakase, S. Yazumi, H. Yamagishi, T. Okanoue, T. Chiba, and A. Hagiwara. 2005. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin. Cancer Res. 11: 6479-6488 https://doi.org/10.1158/1078-0432.CCR-05-0729
  52. Salazar-Onfray, F., T. Nakazawa, V. Chhajlani, M. Petersson, K. Karre, G. Masucci, E. Celis, A. Sette, S. Southwood, E. Appella, and R. Kiessling. 1997. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res. 57: 4348-4355
  53. Scanlan, M. J., I. Gout, C. M. Gordon, B. Williamson, E. Stockert, A. O. Gure, D. Jager, Y. T. Chen, A. Mackay, M. J. O'Hare, and L. J. Old. 2001. Humoral immunity to human breast cancer: Antigen definition and quantitative analysis of mRNA expression. Cancer Immunity 1: 4
  54. Scanlan, M. J., J. D. Gordan, B. Williamson, E. Stockert, N. H. Bander, V. Jongeneel, A. O. Gure, D. Jager, E. Jager, A. Knuth, Y. T. Chen, and L. J. Old. 1999. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int. J. Cancer 83: 456-464 https://doi.org/10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5
  55. Scanlan, M. J., S. Welt, C. M. Gordon, Y. T. Chen, A. O. Gure, E. Stockert, A. A. Jungbluth, G. Ritter, D. Jager, E. Jager, A. Knuth, and L. J. Old. 2002. Cancer-related serological recognition of human colon cancer: Identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 62: 4041-4047
  56. Scanlan, M. J., Y. T. Chen, B. Williamson, A. O. Gure, E. Stockert, J. D. Gordan, O. Tureci, U. Sahin, M. Pfreundschuh, and L. J. Old. 1998. Characterization of human colon cancer antigens recognized by autologous antibodies. Int. J. Cancer 76: 652-658 https://doi.org/10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.0.CO;2-P
  57. Schmits, R., B. Cochlovius, G. Treitz, E. Regitz, R. Ketter, K. D. Preuss, B. F. Romeike, and M. Pfreundschuh. 2002. Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas. Int. J. Cancer 98: 73-77 https://doi.org/10.1002/ijc.10170
  58. Somasundaram, R., R. Swoboda, L. Caputo, L. Otvos, B. Weber, P. Volpe, P. van Belle, S. Hotz, D. E. Elder, F. M. Marincola, L. Schuchter, D. Guerry, B. J. Czerniecki, and D. Herlyn. 2006. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res. 66: 3287-3293 https://doi.org/10.1158/0008-5472.CAN-05-1932
  59. Sonn, C. H., H. R. Yoon , I. O. Seong, M. Chang, Y. C. Kim, H. Kang, S. Suh, and Y. S. Kim. 2006. MethA fibrosarcoma cells expressing membrane-bound forms of IL-2 enhance antitumor immunity. J. Microbiol. Biotechnol. 16: 1919- 1927
  60. Steitz, J., S. Buchs, D. Tormo, A. Ferrer, J. Wenzel, C. Huber, T. Wolfel, M. Barbacid, M. Malumbres, and T. Tuting. 2006. Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin. Int. J. Cancer 118: 373-380 https://doi.org/10.1002/ijc.21349
  61. Sugita, S., H. Takase, C. Taguchi, Y. Imai, K. Kamoi, T. Kawaguchi, Y. Sugamoto, Y. Futagami, K. Itoh, and M. Mochizuki. 2006. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest. Ophthalmol. Vis. Sci. 47: 2547-2554 https://doi.org/10.1167/iovs.05-1547
  62. Sundberg, E. J., M. W. Sawicki, S. Southwood, P. S. Andersen, A. Sette, and R. A. Mariuzza. 2002. Minor structural changes in a mutated human melanoma antigen correspond to dramatically enhanced stimulation of a CD4+ tumor-infiltrating lymphocyte line. J. Mol. Biol. 319: 449- 461 https://doi.org/10.1016/S0022-2836(02)00370-4
  63. Tahara, K., K. Takesako, A. Sette, E. Celis, S. Kitano, and T. Akiyoshi. 1999. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 5: 2236-2241
  64. Theobald, M., J. Biggs, D. Dittmer, A. J. Levine, and L. A. Sherman.1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92: 11993-11997
  65. Thomas, C. M. and C. G. Sweep. 2001. Serum tumor markers: Past, state of the art, and future. Int. J. Biol. Markers 16: 73-86 https://doi.org/10.1177/172460080101600201
  66. Tomkiel, J. E., H. Alansari, N. Tang, J. B. Virgin, X. Yang, P. VandeVord, et al. 2002. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin. Cancer Res. 8: 752-758
  67. Traversari, C., P. van der Bruggen, B. Van den Eynde, P. Hainaut, C. Lemoine, N. Ohta, L. Old, and T. Boon. 1992. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35: 145-152 https://doi.org/10.1007/BF00185107
  68. Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar- Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176: 1453-1457 https://doi.org/10.1084/jem.176.5.1453
  69. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643- 1647 https://doi.org/10.1126/science.1840703
  70. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182: 689-698 https://doi.org/10.1084/jem.182.3.689
  71. Van den Eynde, B. J. and P. van der Bruggen. 1997. T cell defined tumor antigens. Curr Opin Immunol. 9: 684-693 https://doi.org/10.1016/S0952-7915(97)80050-7
  72. Vissers, J. L., I. J. De Vries, M. W. Schreurs, L. P. Engelen, E. Oosterwijk, C. G. Figdor, and G. J. Adema. 1999. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 59: 5554-5559
  73. Vonderheide, R. H., W. C. Hahn, J. L. Schultze, and L. M. Nadler. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673-679 https://doi.org/10.1016/S1074-7613(00)80066-7
  74. Walton, S. M., M. Gerlinger, O. de la Rosa, N. Nuber, A. Knights, A. Gati, M. Laumer, L. Strauss, C. Exner, N. Schalfer, M. Urosevic, R. Dummer, J. M. Tiercy, A. Mackensen, E. Jager, F. Levy, A. Kunth, D. Jager, and A. Zippelius. 2006. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J. Immunol. 177: 8212-8218 https://doi.org/10.4049/jimmunol.177.11.8212
  75. Wang, R. F., P. F. Robbins, Y. Kawakami, X. Q. Kang, and S. A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181: 799-804 https://doi.org/10.1084/jem.181.2.799
  76. Wang, R. F., X. Wang, A. C. Atwood, S. L. Topalian, and S. A. Rosenberg. 1999. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen. Science 284: 1351-1354 https://doi.org/10.1126/science.284.5418.1351
  77. Wang, R. F., X. Wang, and S. A. Rosenberg. 1999. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J. Exp. Med. 189: 1659-1668 https://doi.org/10.1084/jem.189.10.1659
  78. Watson, P. H., S. K. Chia, C. C. Wykoff, C. Han, R. D. Leek, W. S. Sly, K. C. Gatter, P. Ratcliffe, and A. L. Harris. 2003. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br. J. Cancer 88: 1065-1070 https://doi.org/10.1038/sj.bjc.6600796
  79. Zhang, Y., N. Renkvist, Z. Sun, B. Schuler-Thurner, N. Glaichenhaus, G. Schuler, T. Boon, P. van der Bruggen, and D. Colau. 2005. Polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur. J. Immunol. 35: 1066-1075 https://doi.org/10.1002/eji.200425847